Enrich your pipeline

Through the invention disclosure submitted by the inventors and “scouting” activity in Inserm laboratories, Inserm Transfert handles around 300 new invention disclosures and submits some 150 new patent applications annually on targets, products or methods for research and human health applications, in fields such as therapeutics, diagnostics and medical devices.

These new patents enrich a constantly growing portfolio covering the many treatment areas investigated within Inserm (oncology, infection, inflammation, autoimmune diseases, vaccines, cardiovascular health, metabolism, neurology, ophthalmology, respiratory medicine, reproduction, dermatology, etc.). These involve many therapeutic technological approaches (antibodies, peptides, recombinant proteins, cell and gene therapy, biomaterials, oligonucleotides and small molecules, etc.) and diagnostic approaches (biomarkers, patient stratification and precision medicine).

In addition to these patents, which are available through license agreements, there are almost 300 proprietary materials and animal models distributed on a limited basis and governed by in-house or industrial applications (research products and reagents or, more specifically, diagnostic products).

To find out about our licensing opportunities on patents, proprietary materials, animal models and software, please contact our team:  

Boost your external innovation

Inserm’s translational research is a continual source of innovation in terms of discovering new targets, experimental models, and new approaches to therapeutic or diagnostic interventions, allowing for a better understanding of complex diseases.

• Become a partner in Inserm’s cross-cutting programmes:  these combine fundamental, translational, technological and clinical research approaches to meet the major scientific challenges on the subjects of ageing, the Microbiota and population Genomic Variability. Each project groups together exceptional, complementary teams in order to achieve ambitious objectives in partnership with companies, providing a continuum towards economic and societal value creation;
• Co-construct your customized programme: Inserm Transfert provides you with the expertise of a research clinician and access to patient cohorts to identify new targets and biomarkers for stratifying patients and/or testing the relevance of new treatment hypotheses in a collaborative research programme.